Biotechnology News and Research

RSS

Revised Management Guidelines for diagnosing and treating thyroid cancer released

The American Thyroid Association has released new, revised Management Guidelines for the diagnosis and treatment of patients with thyroid nodules and thyroid cancer. The new guidelines are published in Thyroid, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com).

6 Nov 2009

Pfizer extends JAK3 research collaboration with Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated announced today that its research collaboration with Pfizer for JAK3 has been extended by one year. The Research and License Agreement entered into in December 2006 with Wyeth provided for an initial three year research term. Under this extension, Ligand will receive $3.1 million in research payments to continue conducting drug discovery and lead candidate optimization.

6 Nov 2009

USPTO issues Notice of Allowance to NovaDel Pharma

NovaDel Pharma Inc., today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. Patent Application No. 10/671,715, entitled “Buccal, Polar and Non-polar Spray Containing Zolpidem,” which covers a method of treating insomnia by administering zolpidem to humans utilizing NovaMist™ Oral Spray spray technology.

6 Nov 2009

Rice University's new BRC awarded $2M NIH grant to develop an inexpensive test for oral cancer

The National Institutes of Health (NIH) has awarded researchers in Rice University's new BioScience Research Collaborative (BRC) a $2 million Grand Opportunity (GO) grant to develop a fast, inexpensive test for oral cancer that a dentist could perform simply by using a brush to collect a small sample of cells from a patient's mouth.

6 Nov 2009

Amgen announces the results for Phase 3 PRIME '203' trial of Vectibix

Amgen today announced that the Phase 3 PRIME "203" trial evaluating Vectibix® (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival.

5 Nov 2009

Catalent Pharma Solutions, Endotis Pharma forge alliance to develop oral formulations of small-glycol drugs

Catalent Pharma Solutions, the leading provider of advanced oral drug delivery technologies to the pharmaceutical industry, has entered into a strategic alliance with Endotis Pharma for the development of oral formulations of synthetic oligosaccharides.

5 Nov 2009

Environmental Tectonics bags two new contracts worth $700,000 from previous customers

Environmental Tectonics Corporation's Sterilization Systems Group (SSG), a division of ETC's Control Systems Group (CSG), today announced the award of two new contracts for large, industrial sized sterilization systems from previous customers. The combined contract values exceed $700,000.

5 Nov 2009

Abraxis BioScience reports $96.6 million net revenues for third quarter of 2009

Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the third quarter ending September 30, 2009.

5 Nov 2009

FDA grants Abraxis BioScience orphan drug designation for ABRAXANE

Abraxis BioScience, Inc., a fully integrated biotechnology company, today announced that the Office of Orphan Products Development of the Food and Drug Administration (FDA) has granted orphan drug designation to the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the treatment of pancreatic cancer as well as stage IIB-IV melanoma.

5 Nov 2009

New biosensor device may help in combating cancer

A powerful new biosensor developed by European researchers will help identify cells in the immune system that actively suppress tumour growth, then put them to use. Enlisting the patient's own immune system would be like sending reinforcements for resistance fighters.

5 Nov 2009

Oncolytics Biotech reports financial results for the third quarter of 2009

Oncolytics Biotech Inc. today announced its financial results for the three and nine-month periods ended September 30, 2009.

5 Nov 2009

ArQule reports financial results for the fiscal quarter and nine months ended September 30, 2009

ArQule, Inc. today reported its results of operations for the fiscal quarter and nine months ended September 30, 2009.

5 Nov 2009

Second-quarter fiscal 2010 results announced by Repligen

Repligen Corporation today reported results for the second quarter of fiscal year 2010, ended September 30, 2009. Total revenue for the quarter was $5,421,000 compared to total revenue of $5,090,000 for the second quarter of fiscal year 2009 ended September 30, 2008.

5 Nov 2009

Compugen signs research and license agreement with a leading diagnostic company

Compugen Ltd. announced today that it has signed a research and license agreement with a leading diagnostic company covering CGEN-226, a novel biomarker candidate for early detection of preeclampsia.

5 Nov 2009

Phase Forward, Quotient Clinical sign multi-year agreement

Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, today announced a multi-year agreement with Quotient Clinical, which specializes in early development services for a broad range of pharmaceutical and biotech customers.

5 Nov 2009

Can American ginseng relieve health problems?

With the current outbreak of influenza-like illnesses, many people are trying to boost their immune systems with supplements. Ginseng is often a key ingredient, but its therapeutic use may extend far beyond that. Researchers are now investigating whether ginseng can help relieve health problems ranging from diabetes to depression to erectile dysfunction.

5 Nov 2009

Cell Therapeutics reports financial results for the third quarter and nine months ended September 30, 2009

Cell Therapeutics, Inc. today reported recent achievements and financial results for the third quarter and nine months ended September 30, 2009, which included a 45% decrease in the net loss attributable to common shareholders for the nine month period in 2009 compared to the same period in 2008.

5 Nov 2009

Abraxis Health dedicates its new manufacturing facility in Phoenix

Abraxis Health, a fully-integrated personalized healthcare division of Abraxis BioScience, Inc., today announced the dedication of its new manufacturing facility in Phoenix, Arizona. The state of the art biopharma manufacturing plant represents a $70 million investment by LA-based Abraxis, and will create up to 200 high tech jobs.

5 Nov 2009

Bursting common myths about psoriasis

Psoriasis is a real disability that affects approximately one million Canadians. A recent Canadian survey found that the causes and effects of this chronic, recurrent skin disorder are often misunderstood - and the result of these misperceptions can leave a lasting negative impact on those who suffer from this debilitating immune system disease.

5 Nov 2009

InterMune seeks FDA marketing approval for pirfenidone

InterMune, Inc. today announced that it has submitted an electronic New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF). Pirfenidone has been granted Orphan Drug and Fast Track designation by the FDA, and also has been granted Orphan Drug status in Europe.

5 Nov 2009